Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 August 2021 | Story Leonie Bolleurs | Photo Supplied
Prof Carlien Pohl-Albertyn, a successful scientist, is living her dream job, as she gets to pursue her passion for microbiology; a career she wanted to pursue ever since Grade 10.

Prof Carlien Pohl-Albertyn, a professor of Microbiology in the Department of Microbiology and Biochemistry, is the holder of the SARChI Chair in Pathogenic Yeasts at the University of the Free State (UFS). She is leading the Pathogenic Yeast Research Group, studying pathogenic yeast infections and necessary treatment options and bringing hope to many immunosuppressed patients battling HIV/Aids, cancer, diabetics, and other diseases. She also recently co-authored an article on the incidence of fungal infections in COVID-19 patients. 

“This is my dream job, as I get to pursue my passion for microbiology,” says Prof Pohl-Albertyn, who already knew as early as Grade 10 that she wanted to become a microbiologist. “I have always been fascinated by the natural world and have known since childhood that I would become a scientist,” she says. 

An interview with Prof Pohl-Albertyn reveals more about the persons who inspired her, her view on the development of women, and how she approaches her work. 

Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

“The first woman who instilled a love for the biological sciences in me was Miss Steyn, my high school Biology teacher. She had a passion for teaching that inspired me to become a microbiologist.”

Prof Pohl-Albertyn, however, states that there were many other women who constantly inspired her to be a better person. 

“My mother inspires me to take responsibility for my choices; my mother-in-law inspires me to be kinder to others; and my best friends’ mothers inspire me to persevere, even when things are difficult.”

“I am also inspired by my female friends, Ezelle van den Heever, who has shown me that there is always a plan to be made to solve a problem; Trudi O’Neill, who manages to balance high-level research, teaching, and administration with her home life; Alicia Sherriff, from whom I am learning to be more emotionally intelligent; and Janine Allen, who has expanded my horizons and regularly shows me how to look at the world in a completely different way.”

What is your response to current challenges faced by women and available platforms for women development?

“Coming from a fairly male-dominated cultural background, I realise that I have been very privileged to not experience challenges just because I am a woman. I have been able to study and work in a field that values women and men equally and have chosen a very capable and extremely supportive husband, who sees me as an equal.”

She, however, realises that this is not the case for many women, and understands that there are women who were not able to follow their dreams and make their own life choices.

Prof Pohl-Albertyn believes that any opportunity for women to overcome challenges should be encouraged, as a society will ultimately be better if everyone is able to fulfil their greatest potential.

What advice would you give to the 15-year-old you?

This successful scientist, spouse, mother of two sons, daughter, friend, and mentor to many, says that she will advise her 15-year-old self to do everything the way that she has been doing it. “I do not regret anything and would not change my life in any way,” she says. 

What would you say makes you a woman of quality, impact, and care?

“I am a person of quality because of my integrity, work ethic, and commitment to my responsibilities – something that is easy if you enjoy what you do every day.”

“I am a person of impact because of the influence I have on my colleagues, who I always treat with respect, and my students, who I teach to the best of my abilities, and which I hope will serve them well in their careers.”

“I am a person of care because I value the contributions of my colleagues and students to my own growth and development,” remarks Prof Pohl-Albertyn.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept